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A b s t r a c t
Background: Multiple and yet uncertain connections exist between cardiovascular diseases and the nutritional status of 
patients, particularly in relation to cardiovascular treatments. Proton pump inhibitors (PPI) are among the most commonly 
used group of drugs.
Aim: To analyse utilisation of PPI in association with nutritional risk of patients scheduled for rehabilitation after treatment 
for ischaemic and valvular heart disease. 
Methods: Retrospective analyses on a consecutive sample of patients, which included drug utilisation of PPI and nutritional 
risk screening, using a standardised NRS-2002 tool. The patients (n = 536) were divided into groups based on previous 
cardiovascular treatments and use of PPI.  
Results: Nearly half of the patients (244, 46.1%) had PPI in their chronic therapy despite the clinically negligible prevalence of 
conditions that are their fundamental indications. The odds for using PPI in patients with increased nutritional risk, estimated 
by logistic regression, were 3.34 (95% confidence intervals [CI] 2.26–4.94), p < 0.001. Receiver operating curve analyses also 
revealed significant differences of PPI utilisation in connection with NRS-2002 > 3: positive likelihood-ratio (LR) 2.35 (95% CI 
2.10–2.60); negative LR 0.46 (95% CI 0.4–0.6); area under the curve (AUC) 0.720; p < 0.001; as well as the percentage weigh 
loss history > 6.36% (positive LR 2.22 [95% CI 2.00–2.50]; negative LR 0.41 [95% CI 0.30–0.50]; AUC 0.707; p < 0.001).
Conclusions: Utilisation of PPI was found to be of relatively high prevalence and significantly associated with parameters of 
nutritional risk screening. Furthermore, it was in correlation with the age of patients and the existence of chronic kidney dis-
ease, which are well-established predispositions for poor nutritional status. Nutritional risk seems to be additionally negatively 
challenged by utilisation of PPI due to gastric malabsorption and anaemia.  
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INTRODUCTION
Poor nutritional status is connected with inappropriate nu-
tritional intake, decreased absorption, increased metabolic 
demands during acute illness, or major invasive treatment, 
and is frequently found in hospitalised patients [1]. Even 
more important is the fact that increased nutritional risk is 
significantly correlated with clinical endpoints such as rate 
of hospitalisations, duration of hospital stay, prevalence of 
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hospital treatment complications or infections, decreased 
quality of life, as well as increased mortality [2, 3]. Conversely 
to the major global health burden of cardiovascular diseases, 
studies on the existence and clinical dynamics of nutritional 
risk are scarce. 
Proton pump inhibitors (PPI) are dominantly used for 
the treatment of peptic ulcers and gastro-oesophageal reflux 
disease. Optimal treatment endurance should be active for 
a period of between two and eight weeks [4, 5]. Supple-
mentary indications include short courses of treatments for 
prevention of stress ulcers in critically ill patients, as well 
as for primary and secondary prevention of gastrointestinal 
haemorrhage. Investigations concerning pleiotropic effects 
of PPIs reported mediation of secretion to the gastrin and 
insulin [6]. Over the counter and on demand use for alleged 
control of dyspeptic symptoms is probably the most common 
source of PPI overuse. Not surprisingly, PPIs are among the 
most commonly used drugs. Conversely to offered treatment 
benefits, prolonged courses of therapy with PPI are essentially 
burdened with several undesirable side-effects. The discon-
tinuation of therapy occasionally causes transitory rebound 
in symptoms of dyspepsia [7]. Long-lasting PPI treatment is 
considered to increase risk for hip, wrist, and spine fractures, 
although there are no unanimously agreed pathophysiologi-
cal mechanisms [8]. Treatment-induced acid suppression is 
connected with decreased absorption of iron and vitamin B, 
with consequent occurrence of anaemia [9, 10]. Meta-anal-
yses on a large scale population reported on escalation of 
community-acquired pneumonia in a population treated with 
PPI [11]. The thought-provoking decrease of platelet func-
tional response was observed in patients taking a combination 
of thienopyridine and PPIs [12]. Hypomagnesaemia, which 
could be found during prolonged courses of PPI therapy, 
might be responsible for predilection to arrhythmias, e.g. 
atrial tachycardias [13].
Aim of our study was to analyse drug utilisation and 
characteristics of PPI usage in connection with nutritional risk 
screening and its parameters in patients scheduled for reha-
bilitation after acute treatment for ischaemic heart disease, as 
well as a combination of ischaemic and valvular heart disease. 
Ethical approval 
The study was approved by the ethical committee of the 
University Hospital “Thalassotherapia Opatija”. Patients were 
included upon signing informed consent. The study was per-
formed in accordance with the Declaration of Helsinki and 
following good clinical practice guidelines. There were no 
financial compensations for patients or authors.  
METHODS
This study included a sample of consecutive patients sched-
uled for stationary cardiovascular rehabilitation 0–6 months 
after treatment for ischaemic or valvular heart disease. 
Diagnostics covered standard demographics, transthoracic 
cardiovascular laboratory, 12-channel electrocardiography, 
and echocardiography exam. Medical records from previous 
cardiovascular treatments were available for all the patients 
included. Screening for nutritional risk was performed with 
the standardised questionnaire Nutritional Risk Screening 
NRS-2002, approved by the European Society for Clinical 
Nutrition and Metabolism (ESPEN) [14]. The typical range 
of NRS-2002 is between 0 and 7, and increased nutritional 
risk was earlier unanimously defined as NRS-2002 > 3 [14]. 
Patients with usual acute or chronic contraindications for 
cardiovascular rehabilitation were not included.    
Drug utilisation analyses included prevalence of therapy 
with: PPI, angiotensin converting enzyme-inhibitor/angio-
tensinogen receptor blocker, beta-blocker, calcium antago-
nists, loop diuretic, acetylsalicylate/thienopyridine, statins, 
antidiabetics, and warfarin. Of other group of drugs, only the 
relative shares of specific PPIs were presented.  
Anthropometrics 
Waist and hip circumferences (WC, HC) and ratios were meas-
ured by tape measure and expressed in centimetres. Body 
weight was expressed in kilograms, height in metres, and 
body mass index (BMI) was calculated [kg/m2]. The weight 
of patients at the time of previous hospitalisation for treat-
ment of index cardiovascular cause was available for 85% 
of the studied population. Weight lost history (%WLH) was 
expressed as the percentage of lost kilograms from the index 
cardiovascular treatment. 
Cardiovascular risk factors 
Medical history included analyses of prevalence for: arterial 
hypertension, hypercholesterolaemia, chronic renal disease, 
known diabetes mellitus, glucose intolerance, smoking status, 
chronic obstructive pulmonary disease, any disturbance of 
psychological profile, atherosclerotic process and thrombosis, 
atrial fibrillation, past myocardial infarction, and left ventricu-
lar systolic dysfunction (cutoff point set at 50%). 
Statistical analyses
The population and studied groups were analysed with 
descriptive statistics and presented as averages or medians 
combined with standard deviations and ranges. Analyses of 
group data were calculated with c2 tests, whilst data on nu-
meric variables were tested for differences by Mann-Whitney 
U test or Kruskal-Wallis. Connections of PPI utilisation with 
NRS-2002 and other clinical outcomes was done by Spear-
man Rho. Receiver operating curve (ROC) analyses included 
percentage WLH and NRS-2002 score in connection with PPI 
utilisation. Binomial logistic regression models were applied 
for estimation of association between PPI use and increased 
nutritional risk (NRS > 3). Odds for PPI utilisation according to 
patients’ comorbidities were calculated in a polynomial logistic 
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regression model. P < 0.05 was considered significant. Analyses 
were done by a statistician using Statistica 10 for Windows 
(StatSoft Inc., Tulsa, OK, USA), MedCalc 12.2 (MedCalc 
software, Mariakerke, Belgium) and IBM-SPSS12 v 20 (IBM, 
Chicago, IL, USA).
RESULTS
Patients 
The study sample included 536 consecutive patients sched-
uled for cardiovascular rehabilitation, as presented in Table 1. 
Studied cardiovascular aetiologies were as follows: ischae-
mic heart disease in 449 (83.8%) and combined (ischaemic 
and valvular) in 87 (16.2%). The treatment part included 
46 (8.6%) conservatively treated myocardial infarctions, 
223 (41.6%) percutaneous coronary interventions (PCI), and 
267 (49.8%) surgical treatments, of which 88 (16.4%) were 
combined surgical treatments (coronary artery bypass graft 
and valvular surgery). Analyses of patients’ characteristics and 
clinical diagnostics through the groups of PPI utilisation and 
type of heart disease are presented in Table 2.
There were no records of clinically overt acute gastroin-
testinal haemorrhage in the studied population for the period 
after acute cardiovascular treatment. Peptic ulcer disease 
between the postoperative period and rehabilitation was 
documented by endoscopy in six (1.1%) patients. Endos-
copy verified Forrest II–III grades, and there was not a single 
case of Forrest 1.a bleeding. There were no tests applied for 
establishing diagnose of Helicobacter pylori infection in the 
studied period. 
Nutritional Risk Screening 
Mean NRS-2002 in the studied population was 3.3 ± 1.6 (range 
0.0–6.0). The percentage WLH from indication cardiovascular 
treatment was 7.1 ± 4.8% (range 0.0–26.1%). The latter was 
also significantly different in connection with the type of previ-
ous treatments; 4.1 ± 4.1% vs. 3.6 ± 2.5% vs. 10.6 ± 3.6% 
(p < 0.001), for conservative vs. PCI vs. surgical treatments, re-
spectively. NRS-2002 correlated significantly with the age of pa-
tients (Spearman Rho correlation coefficient [Rho-CC] = 0.372; 
p < 0.001) and creatinine (Rho-CC = 0.307; p < 0.001); 
very weakly with BMI (Rho-CC = –0.094; p = 0.030); 
and non-significantly with left ventricular ejection fraction 
(LVEF) (Rho-CC = –0.062; p = 0.155). Percentage WLH 
showed similar trends in correlations; age (Rho-CC = 0.267; 
p < 0.001); creatinine (Rho-CC = 0.207; p < 0.001); BMI 
(Rho-CC = –0.221; p = 0.030); and non-significantly with LVEF 
(Rho-CC = –0.021; p = 0.637). NRS-2002 was significantly 
different in accordance with previous cardiovascular treat-
ments with 2.1 ± 1.3 vs. 2.1 ± 1.1 vs. 4.4 ± 1.1 (p = 0.001), 
respectively, for conservative vs. PCI vs. surgical. Percentage 
WLH outcomes were also congruent with NRS-2002 dynam-
ics, as follows: 4.1 ± 4.1% vs. 3.6 ± 2.5 vs. 10.7 ± 3.6% 
(p < 0.001), respectively. 
PPI therapy
Nearly half of the patients, 244 (45.5%), consumed the 
PPI in their chronic therapy. Utilisation of PPI significantly 
increased the total number of drugs consumed; 6.2 ± 1.8 
vs. 5.8 ± 1.7 (p = 0.030). Relative shares of specific repre-
sentatives are shown in Figure 1.
Table 1. Characteristics of studied patients sample (n = 536)
Parameters Mean ± SD Range
Age [years] 62.6 ± 10.8 23.4–85.9
Height [m] 1.71 ± 0.10 1.45–1.98
Weight [kg] 83.3 ± 14.8 44.4–135.2
Body mass index [kg/m2] 28.5 ± 4.0 18.2–45.9
Waist circumference [cm] 101.2 ± 10.2 68.0–134.0
Hip circumference [cm] 105.2 ± 41.0 1.0–1020.0
WHR 1.08 ± 1.69 0.66–31.80
Percentage weight loss history 7.1 ± 4.8 0.0–26.1
NRS-2002 3.27 ± 1.55 0–7
Cardiovascular risk factors 5.1 ± 1.6 0–9
Erythrocyte count [×1012] 4.46 ± 0.59 2.40–6.02
Haematocrit 0.40 ± 0.05 0.27–0.52
Glucose [mmol/L] 6.7 ± 1.8 4.6–16.4
Urea [μmol/L] 7.14 ± 2.61 1.70–20.30
Creatinine [μmol/L] 104.6 ± 38.5 49.0–403.0
Uric acid [mmol/L] 337.3 ± 99.2 83.0–818.0
Triglycerides [mmol/L] 1.67 ± 3.86 0.42–89.00
Cholesterol [mmol/L] 4.36 ± 1.81 1.14–36.00
HDL-C [mmol/L] 1.00 ± 0.44 0.10–3.30
LDL-C [mmol/L] 2.27 ± 1.00 0.23–8.66
LVEF [%] 49.1 ± 8.1 20–65
Parameters N %
Male 390 72.8
Female 146 27.2
Chronic renal disease 83 15.5
Diabetes 150 28.0
Obesity 175 32.7
Glucose intolerance 68 12.7
Non smoker 194 36.2
Active smoker/recent quitter 165 30.8
Former smoker 177 33.0
COPD 125 23.3
Non-fatal MI 390 72.8
Known atherothrombotic disorder* 140 26.1
*History of peripheral artery disease, carotid disease, cerebrovascular 
stroke, or thromboembolism; SD — standard deviation; WHR — waist-
-to-hip ratio; NRS-2002 — Nutritional Risk Screening; HDL-C — high-
-density lipoprotein cholesterol; LDL-C — low-density lipoprotein 
cholesterol; LVEF — left ventricular ejection fraction; CPOD — chronic 
obstructive pulmonary disease; MI — myocardial infarction 
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PPI utilisation showed significant correlation with the age 
of patients (Rho = 0.198; p < 0.001), WC (Rho = –0.090; 
p = 0.037), HC (Rho = –0.101; p = 0.019), BMI (Rho = –0.137; 
p = 0.002), weight (Rho = 0.206; p < 0.001), percentage 
unintentional WLH (Rho = 0.338; p < 0.001), NRS-2002 
(Rho = 0.386; p < 0.001), creatinine (Rho = 0.103; p = 0.017), 
estimated creatinine clearance (Rho = –0.295; p < 0.001), 
total cholesterol (Rho = 0.120; p = 0.006), high density lipo-
protein (Rho = –0.090; p = 0.038); gamma glutamic trans-
peptidase (Rho = 0.135; p = 0.002), and thyroid-stimulating 
hormone (Rho = 0.096; p = 0.029). There was no correlation 
with LVEF (p > 0.05). Odds for PPI utilisation according to 
patients’ comorbidities were significant in polynomial lo-
gistic regression model: diabetes mellitus 1.02 (0.68–1.52), 
chronic obstructive pulmonary disease 1.15 (0.75–1.74), 
chronic kidney disease 1.16 (0.71–1.91), dyslipidaemia 1.51 
Use of PPIs showed significant differences with the stud-
ied group of treatments; the highest prevalence was found in 
patients treated by surgery 178 (72.1%), whilst PCI treatments 
and conservatively treated myocardial infarctions represented 
only a minor share (p < 0.001). The lowest level of not con-
suming the PPI were found in the group of PCI treatments 
177 (61.2%). Odds for PPI usage depending of the treatment 
applied were calculated using a polynomial logistic regression 
model; PCI = 0.63 (0.08–4.94); conservative = 2.21 (0.28–
–7.60); surgery = 4.74 (0.59–38.12); p < 0.001.
There was no statistical difference between PPI users 
vs. controls for: gender, prevalence of arterial hypertension, dys-
lipidaemia, chronic kidney disease, diabetes, glucose intolerance, 
peripheral artery disease, and atrial fibrillation (all p > 0.05). 
Complete analyses of patients’ characteristics and pharmaceutical 
treatments for the studied groups are shown in Table 3.
Table 2. Characteristics of the studied groups
  Drug utilisation groups Mann Whitney U
Not using PPI
N = 292 (54.5%)
Using PPI
N = 244 (45.5%)
Age [years] 60.5 ± 11.4 65.2 ± 9.5 < 0.001
Height [m] 1.72 ± 0.09 1.69 ± 0.10 < 0.001
Weight [kg] 86.1 ± 14.9 80.1 ± 13.9 < 0.001
Body mass index [kg/m2] 28.9 ± 4.1 27.9 ± 3.7 0.002
Waist circumference [cm] 102.0 ± 10.4 100.3 ± 9.9 0.038
Hip circumference [cm] 104.5 ± 8.0 102.9 ± 7.8 0.020
Waist to hip ratio 1.06 ± 1.41 0.97 ± 0.08 0.594
Percentage weight loss history 5.6 ± 4.2 8.9 ± 4.8 < 0.001
NRS-2002 2.7 ± 1.4 3.9 ± 1.5 < 0.001
Cardiovascular risk factors 5.2 ± 1.6 5.1 ± 1.7 0.646
Erythrocytes count [×1012] 4.7 ± 0.5 4.2 ± 0.6 < 0.001
Haematocrit 0.42 ± 0.04 0.38 ± 0.05 < 0.001
Mean corpuscular volume [fL] 88.2 ± 10.8 89.7 ± 4.9 0.181
Leukocytes [×1012] 7.6 ± 2.0 8.3 ± 2.5 < 0.001
Platelets [×109] 267.2 ± 83.6 344.0 ± 146.3 < 0.001
Glucose [mmol/L] 6.6 ± 1.8 6.8 ± 1.8 0.013
Urea [μmol/L] 7.06 ± 2.71 7.22 ± 2.51 0.125
Creatinine [μmol/L] 102.9 ± 40.3 106.6 ± 36.3 0.017
CGCC [mL/min] 85.6 ± 30.9 68.2 ± 26.2 < 0.001
Uric acid [mmol/L] 341.4 ± 94.0 332.6 ± 104.9 0.199
Triglycerides [mmol/L] 1.47 ± 0.75 1.90 ± 5.64 0.057
Cholesterol [mmol/L] 4.27 ± 2.16 4.47 ± 1.27 0.006
HDL-cholesterol [mmol/L] 1.04 ± 0.46 0.95 ± 0.41 0.038
LDL-cholesterol [mmol/L] 2.15 ± 0.94 2.42 ± 1.05 0.002
Left ventricular ejection fraction [%] 48.8 ± 8.3 49.3 ± 7.9 0.538
Total number of drugs 5.8 ± 1.7 6.2 ± 1.8 0.030
Data presented as mean with standard deviations. Statistically significant values presented in bold. PPI — proton pump inhibitors; NRS-2002 — Nutri-
tional Risk Screening; CGCC — Cockcroft-Gault formula estimated creatinine clearance; HDL — high-density lipoprotein; LDL — low-density lipoprotein 
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(0.59–3.92), atrial fibrillation 1.65 (0.96–2.84), and in-
creased nutritional risk (NRS-2002 ≥ 3) 3.10 (2.07–4.63); 
p < 0.001. Odds for using PPI in patients with increased nutri-
tional risk, estimated by binomial logistic regression, were 3.34 
(95% CI 2.26–4.94); p < 0.001. ROC analyses also revealed 
significant differences of PPI utilisation in connection with 
NRS-2002 > 3 (positive likelihood-ratio [LR] = 2.35, 95% CI 
2.10–2.60; negative LR = 0.46, 95% CI 0.4–0.6; p < 0.001; 
area under the curve [AUC] 0.720); as well as the percentage 
WLH > 6.36% (positive LR = 2.22, 95% CI 2.00–2.50; nega-
tive LR = 0.41, 95% CI 0.30–0.50; p < 0.001; AUC 0.707).
Significant correlations were found with complete blood 
count analyses; erythrocytes counts (Rho = –0.365; p < 0.001), 
haematocrit (Rho = –0.407, p < 0.001), leukocyte counts 
(Rho = 0.156; p < 0.001), and platelets counts (Rho = 0.295; 
p < 0.001), whilst there was no significance for mean cor-
puscular volume (Rho = 0.058; p = 0.180). Critical value of 
haematocrit ≤ 0.38 was found to be a clinically significant dis-
criminative predictor for PPI prescription using ROC analyses; 
sensitivity = 59.4 (95% CI 52.9–65.5); specificity = 80.0 (95% 
CI 74.8–84.4); positive LR = 2.96 (2.60–3.30); negative 
LR = 0.51 (0.40–0.70); AUC = 0.735 (0.696–0.772); 
p < 0.001. Subanalyses of complete blood count in relation 
to PPI utilisation for the studied groups of cardiovascular 
treatments are shown in Table 4.
DISCUSSION
The current study for the first time analysed the connections of 
nutritional status and PPI utilisation in patients recovering from 
acute cardiovascular treatment due to ischaemic or combined 
(ischaemic and valvular) heart disease. The dominant part of 
studied patients was in the sub-chronic clinically stabile phase 
after interventional or non-interventional treatment.  
The combined prevalence of active gastroenterological 
indications was at a relatively low level. Nevertheless, 244 of 
536 patients had a PPI in chronic pharmacotherapy [15]. Even 
more interesting was the fact that consumption was in positive 
correlation with age of patients, despite the potentially less 
favourable side-effects profile in older patients [16]. PCI were 
liaised with the least consumption of PPI, in comparison with 
conservative treatments or surgery, respectively [17]. The exist-
ence of chronic renal disease increased utilisation of PPIs in the 
studied group of patients, which was in line with positive corre-
lation of creatinine concentrations with drug consumption [18]. 
Attention-grabbing connections of PPI utilisation were 
found with anthropometrics and nutritional status of pa-
tients. Most of the patients using PPI weighed less in compari-
son with the group that did not use the drug. Furthermore, 
patients on PPI had a greater extent of unwillingness to lose 
weight after cardiovascular treatment and more pronounced 
nutritional risk [19]. Nutritional risk analysis by NRS-2002 was 
different on basis of cardiovascular treatments as well. Surgical 
treatments were liaised with significant increase in nutritional 
risk, while PCI and conservative treatment were of close out-
put range and lesser extent. NRS showed overall significant 
difference, as well as significant differences of unintentional 
loss of weight among studied treatments. Renal function and 
the age of patient increased the outputs of NRS, as well as the 
increased PPI consumption patterns [20]. Associations of PPI 
utilisation with anthropometrics and increased nutritional risk 
seem to represent clinically underscored primary prevention 
of mucosal lesions and gastrointestinal haemorrhage [21]. 
Although a high proportion of patients used acetylsalicylates, 
the PPI utilisation profile was divergent to the consumption 
of nonsteroidal anti-inflammatory drugs (NSAIDs) and influ-
enced more by the particular cardiovascular treatment. The 
least consumption of PPI was found in the group of patients 
treated with PCI and mandatorily related to acetylsalicylates 
therapy. Conversely, increased utilisation was found with surgi-
cal patients. In both ways, the combined “gastro-angio-cardio” 
protection approach using acetylsalicylic acid and PPI might 
even alter for the worse NSAID-induced enteropathy and 
dysbiosis [22].
The combined effects of PPIs on the haematopoietic 
system were found as well, bearing in mind the fact that 
there was no history of recent bleeding in the studied group 
of patients. Analysis of PPI use revealed a decrease in eryth-
rocyte counts and haematocrit, while the mean corpuscular 
volume of erythrocyte was unchanged. Later was in line with 
earlier observations about PPI-mediated changes in metabo-
lism of vitamin B and gastric absorption of iron [23]. Both 
aetiologies might be even more pronounced in patients with 
increased nutritional risk or in patients of advanced age [23]. 
Figure 1. Structure of prescription for representatives of 
proton pump inhibitor (PPI) group (n = 244). Utilisation of 
different PPIs: pantoprazole 213 (87.3%); esomeprazole  
18 (7.4%); lansoprazole 7 (2.9%); omeprazole 2 (0.8%); 
other/non-classified 4 (1.6%). Data presented for number of 
patients (percentages)
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Table 3. Patients’ characteristics according to studied groups of treatments and proton pump inhibitor (PPI) therapy
Drug utilisation groups c2
Not using PPI Using PPI
Age group < 44 22 (7.6%) 3 (1.2%)
< 0.00145–64 165 (57.1%) 117 (47.4%)
> 65 102 (35.3%) 127 (51.4%)
Obesity BMI < 30 kg/m2 182 (63.0%) 178 (72.4%)
0.021
BMI ≥ 30 kg/m2 107 (37.0%) 68 (27.6%)
Any psychological disturbance No 161 (55.7%) 116 (47.0%)
0.043
Yes 128 (44.3%) 131 (53.0%)
Coronary artery disease No 34 (11.8%) 51 (20.6%)
0.005
Yes 255 (88.2%) 196 (79.4%)
Nonfatal MI No 50 (17.3%) 96 (38.9%)
< 0.001
Yes 239 (82.7%) 151 (61.1%)
Disease Ischemic 254 (87.9%) 195(78.9%)
0.005
Combined 35 (12.1%) 52 (21.1%)
Treatments Conservative 23 (8.0%) 23 (9.3%)
< 0.001PCI 177 (61.2%) 46 (18.6%)
Surgery 89 (30.8%) 178 (72.1%)
NRS-2002 ≥ 3 No 129 (44.6%) 48 (19.4%) < 0.001
Yes 160 (55.4%) 199 (80.6%)
Acetylsalicylic acid No 34 (11.8%) 32 (13.0%) 0.676
Yes 255 (88.2%) 215 (87.0%)
Warfarin No 244 (84.4%) 186 (75.3%) 0.008
Yes 45 (15.6%) 61 (24.7%)
ACE inhibitor No 67 (23.2%) 108 (43.7%) < 0.001
Yes 222 (76.8%) 139 (56.3%)
Beta-blocker No 26 (9.0%) 33 (13.4%) 0.108
Yes 263 (91.0%) 214 (86.6%)
Calcium channel blockers No 222 (76.8%) 197 (79.8%) 0.411
Yes 67 (23.2%) 50 (20.2%)
Diuretic No 226 (78.2%) 150 (60.7%) < 0.001
Yes 63 (21.8%) 97 (39.3%)
Statin No 46 (15.9%) 101 (40.9%) < 0.001
Yes 243 (84.1%) 146 (59.1%)
Statistically significant values presented in bold. BMI — body mass index; MI — myocardial infarction; PCI — percutaneous coronary intervention; 
NRS-2002 — Nutritional Risk Screening; ACE — angiotensin-converting-enzyme
Table 4. Relationship of proton pump inhibitor (PPI) use with the complete blood count for studied groups of treatments. Data 
presented as mean with standard deviation. 
Conservative Percutaneous coronary 
intervention
Surgery 
Not using PPI Using PPI Not using PPI Using PPI Not using PPI Using PPI
Erythrocytes count [×1012] 4.6 ± 0.5 4.6 ± 0.5 4.7 ± 0.4 4.5 ± 0.6 4.6 ± 0.6 4.1 ± 0.6
Haematocrit 0.42 ± 0.04 0.41 ± 0.04 0.42 ± 0.04 0.40 ± 0.04 0.41 ± 0.05 0.36 ± 0.04
Mean corpuscular volume [fL] 90.9 ± 5.5 89.3 ± 4.5 88.1 ± 11.5 89.9 ± 5.1 87.7 ± 10.4 89.7 ± 4.9
Leukocytes [×1012] 8.12 ± 2.41 8.08 ± 2.28 7.67 ± 1.99 8.13 ± 2.08 7.26 ± 1.78 8.44 ± 2.57
Platelets [×109] 269.2 ± 80.8 272.3 ± 91.1 258.2 ± 69.4 286.4 ± 89.1 284.6 ± 105.7 368.3 ± 156.8
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Quantitative analyses revealed statistically significant increase 
in platelet counts in patients using PPIs. However, the effect 
was, in subgroup analyses, found to be more powerfully 
connected with cardiovascular treatments. Less invasive treat-
ments were related with no change, or minimal increase in 
platelets counts, conversely to the significant increase seen 
after surgical treatments. The latter might, in part, explain 
the confounding results of earlier studies of interactions with 
clopidogrel [24].  
Interestingly, the operated patients exhibited the least 
number of pharmaceuticals in chronic therapy, despite the 
fact that they had an equal background of ischaemic heart 
disease. Relative share of PPI in the total quantity of pharma-
cotherapy in the postoperative group was higher and even on 
the expense of statin treatment underutilisation. The differ-
ences in cholesterol concentrations observed between groups 
according to PPI therapy correspond more with consumption 
of antilipemics, which was differently distributed within the 
studied groups of cardiovascular treatments. A significantly 
increased utilisation of PPI was found in patients who were 
taking warfarin as well. Consumption of warfarin was higher in 
the group of surgical treatments, mostly due to the proportion 
of patients with combined ischaemic and valvular disease. 
There were no significant relations between PPI utilisation 
and acetylsalicylic acid or thienopyridine in our patients.
CONCLUSIONS
In conclusion, utilisation of PPI was significantly associated 
with parameters of nutritional risk screening. Furthermore, it 
was in correlation with the age of patients and the existence 
of chronic kidney disease, which are known predispositions 
for nutritional risk. Nutritional risk might be additionally nega-
tively challenged by utilisation of PPI due to the side-effects 
profile, including gastric malabsorption and anaemia. 
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S t r e s z c z e n i e
Wstęp: Istnieją liczne i nieustalone w pełni powiązania między chorobami sercowo-naczyniowymi a stanem odżywienia 
chorych, zwłaszcza w przypadku stosowania leków działających na układ sercowo-naczyniowy. Do grupy najczęściej wyko-
rzystywanych preparatów należą inhibitory pompy protonowej (PPI).
Cel: Celem badania było przeanalizowanie zależności między stosowaniem PPI a ryzykiem związanym ze stanem odżywienia 
pacjentów poddawanych rehabilitacji kardiologicznej po leczeniu choroby niedokrwiennej i zastawkowej serca. 
Metody: Przeprowadzono retrospektywną analizę kolejnych prób chorych obejmującą stosowanie PPI i badanie przesiewowe 
w kierunku ryzyka związanego ze stanem odżywienia, wykorzystując wystandaryzowane narzędzie NRS-2002. Pacjentów 
(n = 536) podzielono na grupy w zależności od wcześniejszego leczenia chorób sercowo-naczyniowych i stosowania PPI.  
Wyniki: Prawie połowa chorych (244 osoby, 46,1%) przyjmowała PPI w ramach długookresowej terapii, mimo że zaburzenia 
stanowiące podstawowe wskazania do ich stosowania występowały u niewielkiego (nieistotnego klinicznie) odsetka badanych. 
Prawdopodobieństwo stosowania PPI u chorych obciążonych zwiększonym ryzykiem związanym ze stanem odżywienia osza-
cowane metodą regresji logistycznej wynosiło 3,34 (95% przedział ufności [CI] 2,26–4,94), p < 0,001. Analiza krzywej ROC 
również wykazała istotną różnicę w stosowaniu PPI w związku z NRS-2002 > 3: iloraz prawdopodobieństwa (LR) otrzymania 
wyniku dodatniego: 2,35 (95% CI 2,10–2,60); LR otrzymania wyniku ujemnego: 0,46 (95% CI 0,4–0,6); pole pod krzywą 
(AUC): 0,720; p < 0,001; oraz procentowa utrata masy ciała > 6,36% (LR wyniku dodatniego: 2,22 [95% CI 2,00–2,50]; LR 
wyniku ujemnego: 0,41 [95% CI 0,30–0,50]; AUC: 0,707; p < 0,001.
Wnioski: Stwierdzono, że leki z grupy PPI były wykorzystywane stosunkowo często. Terapia tymi preparatami wiązała się 
istotnie z parametrami oceny ryzyka związanego ze stanem odżywienia, a także korelowała z wiekiem pacjentów i obecnoś-
cią przewlekłej choroby nerek, będących uznanymi czynnikami predysponującymi do złego stanu odżywienia. Wydaje się, 
że stosowanie PPI dodatkowo zwiększa ryzyko związane ze stanem odżywienia ze względu na zmniejszenie wchłaniania 
w żołądku i niedokrwistość. 
Słowa kluczowe: stan odżywienia, ryzyko związane ze stanem odżywienia, inhibitory pompy protonowej (PPI), choroba 
niedokrwienna serca, choroba zastawkowa serca
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